https://www.live-feeds.com/feed/abbvie-revenue-rises-on-strength-in-immunology-neuroscienceContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/abbvie-revenue-rises-on-strength-in-immunology-neurosciencehttps://www.live-feeds.com/feed/abbvie-revenue-rises-on-strength-in-immunology-neuroscience#u180912Fri, 06 Nov 2026 10:45:43 +0000AbbVie posted third-quarter worldwide revenue of $17.4 billion, marking a 10.3% year-on-year increase driven primarily by its immunology and neuroscience portfolios. Chief Executive Officer Rob Michael noted that nine key products delivered double-digit growth during the quarter. The pharmaceutical giant reported GAAP diluted earnings per share of $2.37 and adjusted diluted earnings per share of $3.82. In response to the strong performance, leadership raised the company's full-year adjusted earnings per share guidance to a range of $13.95 to $13.99, up from the previous forecast of $13.76